Optimal Use of Perampanel in Asian Patients with Epilepsy: Expert Opinion
Yotin Chinvarun,Chin-Wei Huang,Ye Wu,Hsiu-Fen Lee,Surachai Likasitwattanakul,Jing Ding,Takamichi Yamamoto
DOI: https://doi.org/10.2147/TCRM.S316476
2021-07-21
Therapeutics and Clinical Risk Management
Abstract:Yotin Chinvarun, 1 Chin-Wei Huang, 2 Ye Wu, 3 Hsiu-Fen Lee, 4 Surachai Likasitwattanakul, 5 Jing Ding, 6 Takamichi Yamamoto 7 1 Department of Neurology, Phramongkutklao Royal Army Hospital and Medical College, Bangkok, Thailand; 2 Department of Neurology, National Cheng Kung University Hospital College of Medicine, National Cheng Kung University, Tainan, Taiwan; 3 Department of Pediatrics, Peking University First Hospital, Beijing, People's Republic of China; 4 Division of Pediatric Neurology, Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan; 5 Division of Neurology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 6 Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 7 Department of Neurosurgery, Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Hamamatsu, Japan Correspondence: Takamichi Yamamoto Department of Neurosurgery, Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Hamamatsu, Shizuoka, 430-8558, Japan Tel +81 53 474 2222 Fax +81 53 474 3094 Email Perampanel is a once-daily, first-in-class AMPA receptor antagonist approved for the treatment of epilepsy and exhibits broad-spectrum efficacy in a range of seizure types when used as both monotherapy and adjunctive therapy. Clinical studies and real-world evidence have demonstrated the advantages of initiating perampanel at low doses and utilizing a slow titration strategy. Initiating perampanel at an early stage has also been shown to be associated with better patient outcomes. However, the optimal use and place of perampanel in clinical practice has not yet been clearly defined for the Asian patient population. Use of perampanel in clinical practice varies markedly across the Asia region because of variation in knowledge, attitudes, and practice. There is currently no specific guidance on best practices for prescribing perampanel in Asian patients or how to optimize treatment strategies to maximize adherence. A group of epilepsy experts attended a virtual meeting in September 2020 to discuss their experience with using perampanel in the Asian practice setting, including their views regarding appropriate patient populations, optimal starting and maintenance doses, optimal titration regimens, key barriers to adherence, and prevention and management of adverse events. This article summarizes key clinical and real-world evidence for perampanel and consolidates the experts' opinions on optimization of perampanel prescribing and adherence in real-world practice, providing practical strategies for clinicians to implement to improve outcomes for people with epilepsy in Asia. Keywords: perampanel, epilepsy, real-world experience, Asia Approximately 23 million people in Asia are living with epilepsy, with prevalence varying across countries in the region from 1.5 to 14.0 per 1000 person-years. 1 Despite treatment with anti-seizure medication (ASM), however, more than one-third of patients still experience seizures that remain uncontrolled. 2 Drug-refractory epilepsy is associated with reduced quality of life and increased rates of hospitalization, morbidity, and mortality. 3 In addition, patients whose seizures are poorly controlled face a greater burden of healthcare costs than those whose seizures are in remission. 4 With each subsequent ASM regimen trialed, the probability of achieving seizure freedom diminishes substantially; most patients who gain seizure control do so with the first or second ASM prescribed. 2 Therefore, early selection of an effective ASM for initial monotherapy or as early adjunctive therapy is critical for realizing the best possible therapeutic outcomes. Another key factor contributing to poorly controlled epilepsy is inadequate adherence to ASM therapy. 5 Non-adherence in epilepsy is estimated to range from 30% to 50% of patients, similar to what is observed with other chronic illnesses. 5 Complicated ASM regimens are believed to negatively impact patient adherence, and simplifying treatment strategies by utilizing monotherapy and/or reducing dose frequency can be of benefit. 6 Prescribing an ASM with characteristics that promote adherence contributes to achieving seizure freedom. Perampanel is a first-in-class AMPA receptor antagonist approved for the treatment of epilepsy and has broad-spectrum efficacy. <a href="#cit0007%20c -Abstract Truncated-
health care sciences & services